The AACR Annual Meeting 2019 will highlight the latest work of the best minds in cancer research and medicine from institutions all over the world. This year's program, with the theme of"Integrative Cancer Science • Global Impact • Individualized Patient Care," will be a comprehensive, cu...
https://blog.aacr.org/aacr-annual-meeting-2019-optimizing-pd-1-pd-l1-immune-checkpoint-inhibitor-therapy/ 声明:本公众号所有内容,凡注明原创,在授权转载后须在明显位置注明来源:肿瘤评论。本网注明来源为其他媒体的内容为转载,转载仅作观...
Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Holy See (City Vatican State) Honduras Hong Kong Hungary Iceland India Indonesia Iran (Islamic Republic of) Iraq ...
2. Chung HC, Phia-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studie...
(新浪医药编译/newborn) 文章参考来源: 1、Data for Merck’s KEYTRUDA? (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
2019年美国癌症研究协会年会(AACR Annual Meeting)于3月29至4月3日在美国亚特兰举行,AACR年会是世界上规模最大的癌症研究会议之一,吸引了全球20000多名全球肿瘤专业学者出席。通过在上千份投稿中严格筛选,来自9个国家的15名学者被选中获得GSITA奖,我国有两名优秀学者获得此殊荣。首都医科大学附属北京世纪坛医院肿瘤内科...
Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019. Retrieved April 1, 2019, fromhttps://www.prnewswire.com/news-releases/apexigen-presents-clinical-data-on-cd40-antibody-apx005m-in-metastatic-melanoma-at-the-aacr-annual-meeting-2019-300821411...
[7] Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019. Retrieved April 1, 2019, from https://www./news/home/20190401005392/en/
这款疗法的DCR高达84%,达到一年无进展生存的患者比例也有71%。这款在今年1月斩获美国FDA突破性疗法认定的创新药,有望在将来给我们带来更多惊喜。 参考文献: Proceedings of the American Association for Cancer Research AACR ANNUAL MEETING 2019 · Volume 60...
The American Association for Cancer Research (AACR) held its 110th annual meeting in Atlanta, Georgia (USA), bringing together more than 22,500 researchers in all areas of cancer research, physician-scientists and other healthcare professionals, cancer survivors, patients and advocates. The multidisc...